
All you need to know about: Marfan Syndrome
What is Marfan Syndrome?
Marfan Syndrome is a rare genetic condition that affects the body's connective tissue, the material that supports and holds together skin, bones, blood vessels, and organs. When this tissue is weak or stretched, it can cause a wide range of health issues, especially in the heart, eyes, bones, and joints. The condition is named after French doctor Antoine Marfan, who first described it in 1896.
What are the signs and symptoms of Marfan syndrome?
People with Marfan Syndrome often have a tall and thin build, with long arms, legs, fingers, and toes. Their joints may be unusually flexible, and they often have loose ligaments, meaning their fingers may bend back farther than normal, sometimes even touching the back of their hand. Some may have a curved spine or a chest that sticks out or sinks in. The condition also affects the eyes, often causing the lens inside the eye to slip out of place, known as lens dislocation, which can lead to serious vision problems if not treated in time.
The most serious complications involve the heart and major blood vessels. The walls of the aorta (the main artery carrying blood from the heart) can become weak and stretch too much, leading to aneurysms or aortic dissection, both of which can be life-threatening. Some people also have mitral valve prolapse, where a valve in the heart does not close properly.
Also Read: Telangana govt hospital doctors perform liver transplantation on patient suffering from Marfan's and rare syndrome
Who is at risk?
Marfan Syndrome affects about 1 in 10,000 people. It is usually inherited from a parent, but in some cases, it can occur as a new genetic change without a family history. The risk is higher in consanguineous marriages (where partners are closely related), because the chances of passing on certain genetic traits are greater.
Some doctors have suggested that Abraham Lincoln, the 16th President of the United States, may have had features of Marfan Syndrome, such as his tall stature and long limbs. Both men and women are equally affected.
How is it diagnosed and treated?
Marfan Syndrome is diagnosed based on physical signs, eye exams, heart scans like echocardiograms, and genetic testing. Since the symptoms vary and may develop slowly, diagnosis can be delayed unless doctors specifically look for it.
There is no cure for Marfan Syndrome, but it can be managed effectively with the right medical care. Beta-blockers or blood pressure medications like propranolol are often prescribed to reduce stress on the heart and aorta. Regular cardiac checks help monitor the size of the aorta, and surgery may be needed if it becomes dangerously enlarged.
Routine care also includes orthopaedic monitoring for bone or spine issues and regular eye check-ups to catch and treat lens dislocation early. Ignoring vision problems can lead to permanent eyesight loss, especially in children.
Also Read: Cardiac surgeon calls for screening in schools for Marfan Syndrome
What is life like with Marfan Syndrome?
With proper precautions, most people with Marfan Syndrome can lead healthy and productive lives. However, they should avoid strenuous activities, contact sports, or heavy physical work, such as military training or physically demanding jobs which could stress the heart or joints. Regular check-ups with a cardiologist, ophthalmologist, and orthopaedic specialist are essential to monitor and manage the condition over time.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


United News of India
a day ago
- United News of India
Servier India launches ‘Ivosidenib' Tibsovo
Kochi, Jun 10 (UNI) Servier India, a subsidiary of the leading French pharmaceutical Servier Group, has announced the launch of Ivosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma, with an isocitrate dehydrogenase-1 (IDH1) mutation. Servier India received the approval on 14th May 2025, from Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of the medication. Acute myeloid leukemia is a challenging hematological malignancy. Studies indicate that only about 30–40 percent of AML patients in India receive adequate treatment, with high mortality rates due to rapid disease progression and infections. Cholangiocarcinomas (CCA) are rare tumours originating from the bile duct. Due to their asymptomatic nature, they are usually diagnosed when the disease is advanced. The announcement marks a significant advancement in the management of the mentioned rare and difficult-to-treat cancers in India, addressing a critical unmet medical need. Aurélien Breton, Managing Director, Servier India, said, 'Our focus is to advance oncology care by bringing innovative, precision medicines to patients who need them the most." "By prioritizing access and working to make treatment options affordable to patients, we are dedicated to bridging critical gaps in cancer care across the country. This launch will support healthcare providers with targeted treatment options and ultimately improve survival outcomes and quality of life for patients throughout India.' IDH1 mutation occurs in approximately 7–14 percent of AML patients in India, making targeted mechanisms especially relevant for this subset. 'This therapy represents a significant therapeutic option in the treatment of AML and Cholangiocarcinoma. For healthcare professionals, this precision therapy offers a new, effective option that can improve patient outcomes where traditional treatments have limited success. It highlights the benefits of targeted therapy and caliber of innovation in enhancing lives and advancing cancer care in India.', highlighted Dr. Pranav Sopory, Medical and Patient Affairs Director, Servier India. By introducing these advanced therapies, Servier India reaffirms its commitment to advancing innovative cancer treatments that improve clinical outcomes and enhance the quality of life of patient. UNI DS BD


Time of India
3 days ago
- Time of India
Luxury skincare expansion: L'Oreal acquires majority stake in Medik8; announces 1 billion Euro deal
Cosmetics maker L'Oreal agreed to acquire a majority stake in British skincare brand Medik8, in a strategic move to strengthen its presence in the booming skincare market. The French beauty giant announced the deal on Monday, though financial terms were not disclosed. The transaction, which sees UK-based private equity firm Inflexion selling its majority holding, reportedly values Medik8 at around 1 billion Euro, according to a source familiar with the matter. Inflexion will retain a minority share, while L'Oreal has secured the option to eventually buy out all remaining shareholders, Reuters reported. 'We are delighted to welcome Medik8 to the L'Oréal family. As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio,' Cyril Chaupuy, president of L'oreal Luxe said. 'This acquisition further strengthens L'Oreal's luxe portfolio, adding a premium science-backed skincare brand with a proven track record of success, with strong potential for global growth,' the company said in a statement. L'Oreal will begin consolidating Medik8's sales once the transaction officially closes. The acquisition is expected to be finalised in the coming months, pending regulatory approvals and standard closing conditions. Simon Coble, CEO of Medik8 also expressed excitement on the brand's behalf. 'I am delighted to be joining forces with a company which shares our vision for the brand's future growth and whose core values align with our deep commitment to science, innovation and above all, results without compromise. I look forward to the next stage in Medik8's journey, as we work together to bring our innovative products to a wider audience.' Founded in the UK, Medik8 has built a loyal customer base with its vitamin A-focused anti-ageing creams and serums. The brand is seen as a natural fit for L'Oreal's luxury division, which includes skincare and fragrance names such as Lancome, Aesop, and Miu Miu. Last year, sales in L'Oreal's luxe segment grew by just 2.7%, its weakest performance across divisions, as inflation pushed consumers toward more affordable alternatives. However, the unit scrored better than rival LVMH's beauty arm. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now


Time of India
3 days ago
- Time of India
L'Oreal buys British skincare brand Medik8
HighlightsL'Oreal is set to acquire the British skincare brand Medik8, enhancing its portfolio in the rapidly expanding dermatological skincare market. Medik8 specializes in vitamin A-based anti-aging creams and serums, and L'Oreal aims to strengthen its presence in existing markets while expanding globally. L'Oreal's dermatological beauty division has been its fastest-growing sector, achieving revenues of 7 billion euros in the previous year, driven by increasing consumer interest in science-backed skincare products. L'Oreal is to acquire British skincare brand Medik8 , its owner, Britain-based private equity firm Inflexion, said on Monday, boosting the French cosmetics giant's offering in the fast-growing dermatological skincare market . The size of the deal was not disclosed. Medik8 focuses on vitamin A-based anti-ageing creams and serums. "The partnership with L'Oreal will allow Medik8 to deepen its presence in existing markets and expand globally. As part of the transaction, Inflexion will retain a minority shareholding in Medik8," the private equity firm said in a statement. L'Oreal's dermatological beauty division, which includes major brands like CeraVe , La Roche-Posay , and SkinCeuticals , has been its fastest growing in recent years, reaching revenues of 7 billion euros ($7.99 billion) last year, after growing almost 10% on the year before. The business, which also has the highest profit margin among its four divisions, has boomed on growing consumer interest in science-backed products, though growth has slowed recently due to rising competition. L'Oreal executives said this year they were pursuing acquisitions and looking to revive flagging growth. The company acquired Korean skincare brand, Dr.G, in December and also bought a minority stake in Oman-based perfume house Amourage last year.